Search - tctmd.com

Displaying 1 - 20 of 132

Sort: Relevancy | Date

Hints of a Mortality Benefit With TTVR at 2 Years: TRISCEND II

News Conference News ACC 2026

Hints of a Mortality Benefit With TTVR at 2 Years: TRISCEND II

Yael L. Maxwell

April 07, 2026

DIG-RHD: Digoxin Effective in Rheumatic Heart Disease

News Conference News ACC 2026

DIG-RHD: Digoxin Effective in Rheumatic Heart Disease

Michael O'Riordan

April 06, 2026

Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD

News Conference News ACC 2026

Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD

April 02, 2026

SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

News Conference News ACC 2026

SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

March 30, 2026

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

News Conference News ACC 2026

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Michael O'Riordan

March 29, 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

News Conference News ACC 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

Yael L. Maxwell

March 29, 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

News Conference News ACC 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

March 28, 2026

HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE

News Conference News ACC 2026

HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE

March 28, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

March 31, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

April 16, 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

April 07, 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

April 06, 2024

What’s Going to Be Hot at ACC 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

April 01, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.